Boven E - Search Results

1

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.

Treskes M, Boven E, van de Loosdrecht AA, Wijffels JF, Cloos J, Peters GJ, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Among authors: boven e. Eur J Cancer. 1994;30A(2):183-7. doi: 10.1016/0959-8049(94)90084-1. Eur J Cancer. 1994. PMID: 8155393

2

Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.

Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJ. Treskes M, et al. Among authors: boven e. Cancer Res. 1992 Apr 15;52(8):2257-60. Cancer Res. 1992. PMID: 1313740

3

Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, Fodstad O, Langdon S, Fiebig HH. Boven E, et al. Cancer Res. 1992 Nov 1;52(21):5940-7. Cancer Res. 1992. PMID: 1394220 Clinical Trial.

4

Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies directed against intracellular antigens.

Haisma HJ, Pinedo HM, Silva CA, Boven E. Haisma HJ, et al. Among authors: boven e. J Immunol Methods. 1992 Sep 18;154(1):55-60. doi: 10.1016/0022-1759(92)90212-c. J Immunol Methods. 1992. PMID: 1401943

5

Malignant Leydig cell tumor of the testis in complete remission on o,p'-dichlorodiphenyl-dichloroethane.

van der Hem KG, Boven E, van Hennik MB, Pinedo HM. van der Hem KG, et al. Among authors: boven e. J Urol. 1992 Oct;148(4):1256-9. doi: 10.1016/s0022-5347(17)36878-7. J Urol. 1992. PMID: 1404649

6

Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.

Molthoff CF, Buist MR, Kenemans P, Pinedo HM, Boven E. Molthoff CF, et al. Among authors: boven e. J Nucl Med. 1992 Nov;33(11):2000-5. J Nucl Med. 1992. PMID: 1432162 Free article.

7

The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.

Boven E, Hendriks HR, Erkelens CA, Pinedo HM. Boven E, et al. Br J Cancer. 1992 Dec;66(6):1044-7. doi: 10.1038/bjc.1992.407. Br J Cancer. 1992. PMID: 1457343 Free PMC article.

8

A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.

Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WJ, Pinedo HM. Haisma HJ, et al. Among authors: boven e. Br J Cancer. 1992 Sep;66(3):474-8. doi: 10.1038/bjc.1992.298. Br J Cancer. 1992. PMID: 1520585 Free PMC article.

9

Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.

Haisma HJ, Boven E, van Muijen M, De Vries R, Pinedo HM. Haisma HJ, et al. Among authors: boven e. Cancer Immunol Immunother. 1992;34(5):343-8. doi: 10.1007/BF01741556. Cancer Immunol Immunother. 1992. PMID: 1540981 Free PMC article.

10

Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts.

Molthoff CF, Pinedo HM, Schlüper HM, Rutgers DH, Boven E. Molthoff CF, et al. Among authors: boven e. Int J Cancer. 1992 Apr 22;51(1):108-15. doi: 10.1002/ijc.2910510120. Int J Cancer. 1992. PMID: 1563830

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters